Table 1 Patient characteristics of the German compassionate-use-program (CUP) for FTD/TPIP
Characteristics | Number of Patients in the German FTD/TPI CUP | % of Patients in the German FTD/TPI CUP |
|---|---|---|
Patients (application by medical practitioner) | 254 | – |
Non-eligible patients | 6 | – |
Eligible patients without treatment onset | 22 | – |
Eligible patients with Lonsurf treatment onset | 226 | 100% |
Mean age (years) | 63.15 | |
< 60 years | 83 | 36.7% |
< 70 years | 75 | 33.2% |
> 70 years | 68 | 30.1% |
Sex | ||
Male | 132 | 58.4% |
Female | 94 | 41.6% |
ECOG performance statusa | ||
0 | 63 | 28% |
1 | 140 | 62.2% |
≥ 2 | 22 | 9.8% |
Vital signs | ||
Mean height (cm) | 172.1 | – |
Mean weight (kg) | 74.2 | – |
Mean body mass index (kg/m2) (range) | 25 (14.7–43.6) | – |
Mean body surface area (m2)c | 1.87 | |
Mean daily dose of FTD/TPI | 130 mg | |
Colorectal surgery | ||
Yes | 201 | 88.9% |
No | 25 | 11.1% |
KRAS statusa | ||
Wild type | 103 | 46.4% |
Mutant | 119 | 53.6% |
Time from diagnosis of metastatic disease | ||
< 24 months | 55 | 24.3% |
≥24 months | 171 | 75.7% |
Prior use of Regorafenib | ||
Yes | 76 | 33.6% |
No | 150 | 66.4% |
Adjuvant chemotherapyd | ||
Yes | 82 | 36.9% |
No | 140 | 63.1% |